<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Pharmacology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DE32C476-09A8-4BCA-A101-9312BFB03827"><gtr:id>DE32C476-09A8-4BCA-A101-9312BFB03827</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:otherNames>Clive</gtr:otherNames><gtr:surname>Anthony</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/19936B44-1D65-4B64-A24C-699D71A67236"><gtr:id>19936B44-1D65-4B64-A24C-699D71A67236</gtr:id><gtr:firstName>Sandra</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Campbell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0500853"><gtr:id>E8F8B045-72F5-4838-A701-D62A603056E0</gtr:id><gtr:title>Macrophage participation in the hepatic response to acute CNS injury.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500853</gtr:grantReference><gtr:abstractText>We are committed to improving public engagement in science and we will ensure that work carried under under this proposal will be communicated to those outside the scientific community. We have established a web site to disseminate details of our research (www.pharm.ox.ac.uk). If the application is successful, the lay summary will be placed on the web sites, which will be updated as the milestones are reached. We have given, and will be giving, public lectures on the theme of this proposal, we are also involved in a local Schools science programme, and we will release items about our work to the Oxford University Press Office after they have been published in peer-reviewed journals.</gtr:abstractText><gtr:technicalSummary>Local tissue inflammation is also accompanied by regulatory responses in organs away from the primary injury site, which is known as the systemic Acute Phase Response (APR). Injury to the brain or spinal cord also generates an APR. We have discovered, using GeneChip analysis, convention molecular biology, and immuno methods, that the APR after brain injury results in the activation of cells in the liver to produce molecules, known as chemokines, which increase the number of immune cells circulating in the blood. These increased numbers of immune cells migrate not only into the brain where they damage nerve cells, but also into the liver where they cause injury. There is now a need to understand the signalling events that regulate this system and to learn more about the cell populations that are responsible for steering the hepatic APR to CNS injury. Under this proposal, we will test our hypothesis that resident microglia in the brain and Kupffer cells in the liver are the primary mediators of the hepatic APR. We will employ three strategies to target macrophage function in the periphery and in the CNS: (1) we will use newly developed CD11b-HSVTK transgenic mice to achieve microglial paralysis, (2) we will employ peripheral injections of clodronate filled liposomes to selectively deplete Kupffer cells in the liver, and (3) we will suppress Kupffer cell function by the use of a replication deficient adenovirus expressing the IkBa super-repressor gene, which will block NFkB activity. In this way, we expect to discover that elimination or suppression of microglial function in the brain will prevent the initiation of an acute phase response to CNS injury and that the Kupffer cell inactivation will lead to a decrease in the production of hepatic chemokines and a decrease in the mobilisation and recruitment of neutrophils to the liver and to the brain. Furthermore, it is still unclear how macrophage populations contribute to the febrile response. We will use telemetry to discover how microglial paralysis or Kupffer cell depletion contributes to the febrile response initiated by CNS injury. Understanding the cellular and molecular pathways that control the liver-brain axis in the inflammatory response to brain injury will open up therapeutic avenues that can be exploited for clinical treatments to reduce damage to the brain and spinal cord, a significant cause of human morbidity.</gtr:technicalSummary><gtr:fund><gtr:end>2009-07-29</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-07-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>248482</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Centre for Neuroimaging</gtr:department><gtr:description>Epilepsy</gtr:description><gtr:id>ACF02E4C-D567-4A4B-9510-D67E3697E8AD</gtr:id><gtr:impact>The manuscript has been submitted, but has not been accepted. However, the following abstract has been accepted for presentation at&amp;nbsp;http://www.epilepsyrhodes2010.org/&amp;nbsp;and could be presented as a outcome of the collboration. We have also submitted two grants on the basis of this collaboration; one the EU entitled INDICATE, and an application for a John Fell award here in Oxford.</gtr:impact><gtr:partnerContribution>Post-doctoral salary</gtr:partnerContribution><gtr:piContribution>Provision of histology, molecular biology and imaging reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>8F06BB60-936C-4E54-8196-2DCE57E393B4</gtr:id><gtr:impact>A description of the science we do including discussion aboout the ethics of animal experimentation.

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have developed a new platform for imaging. See pubs.</gtr:description><gtr:id>1A759C68-35D7-4F15-839D-16AA3C1A498F</gtr:id><gtr:impact>Commercial in confidence</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO2008035069?</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Multimeric iron oxide particles</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention provides a tumour vasculature permeabilising molecule for use in permeabilising vasculature of a tumour for treating, detecting or diagnosing said tumour wherein said tumour vasculature permeabilising molecule is formulated for systemic administration to said patient. A composition comprising a tumour vasculature permeabilising molecule and an appropriate anticancer agent or imaging agent, and a method of treatment or a method of detecting the presence or absence of a tumour are also provided.</gtr:description><gtr:id>F714542C-3AFD-4387-98B6-35311EA15F31</gtr:id><gtr:impact>Commercial in Confidence</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO2011070358</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Tumour vasculature permeabilising agents</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Commercially sensitive information</gtr:description><gtr:id>81F023BB-38E8-4B76-9C22-90BB51876BFF</gtr:id><gtr:impact>Commercially sensitive information</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Adjunct therapby for brain cancer</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Oxford Contrast</gtr:companyName><gtr:description>The company is seeking to produce targeted contrast agent for use in MRI and PET; http://www.oxfordcontrast.com/</gtr:description><gtr:id>96C420AC-41C3-4EDD-928B-45AC6FA76BB4</gtr:id><gtr:impact>First round funding expected Jan 2010</gtr:impact><gtr:yearCompanyFormed>2009</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/260A1133-34CC-46F3-B57C-B161FFC9BA0F"><gtr:id>260A1133-34CC-46F3-B57C-B161FFC9BA0F</gtr:id><gtr:title>Comparison of MRI signatures in pattern I and II multiple sclerosis models.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d16323e9381b6d103fd3e71f876879b0"><gtr:id>d16323e9381b6d103fd3e71f876879b0</gtr:id><gtr:otherNames>Serres S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/768BA198-D97D-419D-8274-E99CE2A22692"><gtr:id>768BA198-D97D-419D-8274-E99CE2A22692</gtr:id><gtr:title>Hepatic nuclear factor kappa B regulates neutrophil recruitment to the injured brain.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bc117e727538516535f26bb466da33fc"><gtr:id>bc117e727538516535f26bb466da33fc</gtr:id><gtr:otherNames>Campbell SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/75BE7A12-4BBC-4C9E-904A-29447514E3D0"><gtr:id>75BE7A12-4BBC-4C9E-904A-29447514E3D0</gtr:id><gtr:title>Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1542e4537b2a55a3e6754d8be67f31ea"><gtr:id>1542e4537b2a55a3e6754d8be67f31ea</gtr:id><gtr:otherNames>van Kasteren SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E0EE94E-48A1-4AED-B6AC-9D3BBB8ED8BD"><gtr:id>7E0EE94E-48A1-4AED-B6AC-9D3BBB8ED8BD</gtr:id><gtr:title>Expanding the diversity of chemical protein modification allows post-translational mimicry.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1542e4537b2a55a3e6754d8be67f31ea"><gtr:id>1542e4537b2a55a3e6754d8be67f31ea</gtr:id><gtr:otherNames>van Kasteren SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5C767009-30FD-4C19-8428-3AA28C77F6DA"><gtr:id>5C767009-30FD-4C19-8428-3AA28C77F6DA</gtr:id><gtr:title>Liver Kupffer cells control the magnitude of the inflammatory response in the injured brain and spinal cord.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bc117e727538516535f26bb466da33fc"><gtr:id>bc117e727538516535f26bb466da33fc</gtr:id><gtr:otherNames>Campbell SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B12F9A6-257D-49DA-A11A-B6F4F77C8C38"><gtr:id>1B12F9A6-257D-49DA-A11A-B6F4F77C8C38</gtr:id><gtr:title>Inflammatory responses in the rat brain in response to different methods of intra-cerebral administration.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c8d70bd8f862a34d4fcd1fdb1ea1633"><gtr:id>5c8d70bd8f862a34d4fcd1fdb1ea1633</gtr:id><gtr:otherNames>McCluskey L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/39DC051B-A0FE-4554-926C-75F409E93649"><gtr:id>39DC051B-A0FE-4554-926C-75F409E93649</gtr:id><gtr:title>A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90af07a5a92975df0089e5c5871529f3"><gtr:id>90af07a5a92975df0089e5c5871529f3</gtr:id><gtr:otherNames>von Zur Muhlen C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FCA3782-280B-4C9B-ABC2-D1DCAE5182E3"><gtr:id>9FCA3782-280B-4C9B-ABC2-D1DCAE5182E3</gtr:id><gtr:title>Systemic inflammatory response reactivates immune-mediated lesions in rat brain.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d16323e9381b6d103fd3e71f876879b0"><gtr:id>d16323e9381b6d103fd3e71f876879b0</gtr:id><gtr:otherNames>Serres S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500853</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>